Fact checked byChristine Klimanskis, ELS

Read more

December 30, 2022
1 min read
Save

Top five ophthalmology blogs from 2022

Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio/OSN’s top blog posts of the year featured commentaries on the challenges of transitioning to office-based surgery and generic drugs for the treatment of dry eye disease.

Read these and other top blogs from 2022 below.

Eye doctor discussion
Healio/OSN’s top blog posts of the year featured commentaries on the challenges of transitioning to office-based surgery and generic drugs for the treatment of dry eye disease.
Source: Adobe Stock.

BLOG: The five Ss of office-based surgery

Finishing a cataract surgery informed consent discussion, we are asked most commonly by patients, “When can I get it done?” Wouldn’t it be nice if we could look at our watch and say, “Both of your eyes are dilated — let’s adjust the chair.” Read more.

BLOG: Generic Restasis upends dry eye marketplace

Whoa! That sure happened fast. Did you see that coming? The whole dry eye marketplace turned upside down in — what? — 6 weeks? Read more.

BLOG: IRIS Registry Industry Report summarizes highlights of 2021 research

Before the 2022 American Academy of Ophthalmology meeting, Verana Health, the technology, data and analytics partner for the Academy’s IRIS Registry, shared its 2021 IRIS Registry Industry Report. Read more.

BLOG: First-line glaucoma therapy: What does it take to change clinical practice?

Laser trabeculoplasty was described in 1979 and involved an argon modality to noninvasively treat the trabecular meshwork. Read more.

BLOG: PE, PPM and MSO: The alphabet soup of physician practice consolidation

As we all know, consolidation in the physician practice space, most often by platforms backed by private equity, has been occurring, and arguably increasing, for several years now. Read more.